Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research: ADA 2019
The DiRECT Study: Analysis of Patients With Type 2 Diabetes Remission
New Recommendations for Time In Range Goals Using A CGM
21-Year Follow-up of STENO-2: Reducing Strokes and Increasing Life Expectancy
MOST POPULAR ARTICLES OF THE MONTH
#1 Old Malaria Drug Effective In Reducing Blood Glucose
Editor's Note
Our good friend — and gadget wearing friend — from Diabetic Investor, David Kliff, was at the recent ADA Scientific Sessions and he was talking about TIR. This is the new standard for measuring control of insulin-using diabetes patients. For those of you who don’t know, TIR means “time in range.” This refers to the amount of time per day the patient is between 70 and 180 mg/dl.
Although this sounds like a great way to justify the use of CGM and Insulin Pump combination, there is a new study out that points to the validity of using TIR to successfully manage your patient, and our FAMU PharmD Candidate, Maya Rudolph, has an overview of the reasons these 3 letters will likely become the standard of care going forward.
Dave Joffe
Editor-in-chief
Newsflash: FDA approves new treatment for pediatric patients with type 2 diabetes
The U.S. Food and Drug Administration approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
TOP STORIES -- Diabetes News and Research
Data announced at the 79th annual Scientific Sessions of the ADA shows restoration of beta cell function is possible.
The use of continuous glucose monitoring expanding into clinical practice.
The results of the STENO-2 study assessing the benefit of intensified therapy on risk of stroke.
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.